ArticleFrontiers in psychiatry2026
Associations between fear of cancer recurrence and post-traumatic growth in patients with primary liver cancer: a latent profile analysis and mediation analysis.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Promoting post-traumatic growth in patients with liver cancer is of great significance for improving their quality of life and psychosocial adaptation. Previous studies have demonstrated that fear of cancer recurrence (FCR) is a risk factor that hinders post-traumatic growth (PTG). However, existing research often overlooks the heterogeneity of fear of cancer recurrence, and the pathway differences between distinct latent classes and post-traumatic growth remain unclear. Therefore, this study aims to identify the latent classes of fear of cancer recurrence in patients with primary liver cancer and to examine the mediating roles of perceived social support and self-efficacy between different classes and post-traumatic growth. Methods: The cross-sectional survey was organized between February and December 2025. Patients with primary liver cancer from a tertiary hospital in Guangzhou city were recruited through convenience sampling method. The levels of FCR, perceived social support, self-efficacy, and PTG were measured using paper-based questionnaires, and the relationships among variables were analyzed using Pearson correlation analysis, latent profile analysis, and multicategorical independent variable mediation analysis. Results: Three latent profiles of FCR were identified: low fear-psychologically well-adapted group (29.32%), high fear-social functioning concerns group (35.50%), and moderate-to-high fear-treatment concerns group (35.18%). Analysis of influencing factors showed that type of medical insurance, presence of comorbidities, and occupational status were predictors of different latent classes of fear of cancer recurrence in patients with primary liver cancer (P < 0.05). The differences were found in the total scores and subscales of perceived social support, self-efficacy, and PTG among patients with different latent FCR profiles. Mediation analysis showed that, with the low fear-psychologically well-adapted group as the reference, the relative mediation effects were significant for both the high fear-social functioning concerns group and the moderate-to-high fear-treatment concerns group. Conclusion: Fear of cancer recurrence demonstrates marked heterogeneity across individuals diagnosed with primary liver cancer. Clinicians should implement targeted interventions for patients with different FCR profiles to mitigate its negative impact and promote psychological growth by activating their social support systems and enhancing self-efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.